Pursuant to Regulation 30 of SEBI LODR, 2015, we hereby inform you that the Company has approved the NephroPlus Employee Stock option scheme 2026 in the Board meeting held on June 22, 2026 ....

Nephrocare Health Services Ltd's board approved the NephroPlus Employee Stock Option Scheme 2026, contemplating the grant of up to 20,06,814 equity shares, representing about 2% of current paid-up capital, subject to shareholder approval. Concurrently, the company approved providing collateral/security support of up to INR 70 Crore to NephroPlus Kidney Services Company, its overseas step-down wholly-owned subsidiary in Saudi Arabia. This support aims to enable the subsidiary to avail credit facilities, superseding a prior approval for a joint venture due to a revised operating structure in Saudi Arabia.